Your browser doesn't support javascript.
loading
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
Basho, Reva K; Yam, Clinton; Gilcrease, Michael; Murthy, Rashmi K; Helgason, Thorunn; Karp, Daniel D; Meric-Bernstam, Funda; Hess, Kenneth R; Valero, Vicente; Albarracin, Constance; Litton, Jennifer K; Chavez-MacGregor, Mariana; Hong, David; Kurzrock, Razelle; Hortobagyi, Gabriel N; Janku, Filip; Moulder, Stacy L.
Afiliación
  • Basho RK; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Yam C; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Gilcrease M; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Murthy RK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Helgason T; Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Karp DD; Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hess KR; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Valero V; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Albarracin C; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Litton JK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Chavez-MacGregor M; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hong D; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kurzrock R; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hortobagyi GN; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Janku F; Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Moulder SL; Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Oncologist ; 23(11): 1300-1309, 2018 11.
Article en En | MEDLINE | ID: mdl-30139837
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Serina-Treonina Quinasas TOR / Neoplasias de la Mama Triple Negativas Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Serina-Treonina Quinasas TOR / Neoplasias de la Mama Triple Negativas Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido